glycemic levels and lower costs, but previous research on adherence has typically involved oral antidiabetic medication or insulin. This study examines how adherence and persistence to once-daily liraglutide impact glycemic control and economic outcomes in a realworld population of adult type 2 diabetes (T2D) patients. Methods: A retrospective cohort study using administrative claims data from July 2009 through September 2013. Patients aged C18 years with T2D treated with liraglutide were identified (index date = first liraglutide prescription). Adherence was based on the proportion of days covered (PDC); with PDC C0.80 classified as adherent. Non-persistent patients were those with a gap in therapy of [90 days. Lab results for glycated hemoglobin (A1C) were used to identify whether patients achieved target levels of \7.0% and B 6.5%, or experienced a reduction of C1.0% in A1C from pre-index (baseline) to post-index (follow-up).
Logistic regression was used to estimate the likelihood of achieving the A1C goals, adjusted for baseline characteristics. Diabetes-related medical, pharmacy, and total costs were modeled and estimated for the adherence and persistence cohorts. Results: A total of 1321 patients were identified. The mean PDC was 0.59 and 34% of patients were classified as adherent, while 60% were persistent over 12 months of followup. Adherent and persistent patients were more likely to achieve each of the A1C goals than their non-adherent and non-persistent counterparts after adjusting for patient characteristics. Adherence and persistence were associated with higher adjusted diabetes-related pharmacy and total healthcare costs during follow-up; whereas persistent patients had Electronic supplementary material The online version of this article (doi:10.1007/s12325-015-0199-z) contains supplementary material, which is available to authorized users.
INTRODUCTION
In 2012, 29.1 million people in the US had diabetes (roughly 9% of the US population), including over 8 million who were undiagnosed [1] . Type 2 diabetes (T2D) represents the large majority of diabetes cases (90-95%) [1] . The economic burden of diabetes is substantial, with roughly $245 billion in total direct and indirect costs in the US in 2012, including $176 billion in direct medical costs [1, 2] . Diabetes is the leading cause of blindness, end-stage renal disease, and non-traumatic lower-extremity amputations, and is a major risk factor for coronary artery disease and stroke [3] . In 2010, diabetes was the seventh leading cause of death in the US [1] .
Treating diabetes may involve adjustments to diet and lifestyle, as well as pharmacotherapy. The main goal of treatment is to maintain blood glucose to reduce the risk of known complications [4] . The American Diabetes Association recommends that the target level for glycated hemoglobin (A1C) is less than 7% [5] , although only 57% achieved that goal in 2003-2006 [6] . The American Association of Clinical Endocrinologists recommends a target for A1C of B6.5% [7] .
Metformin (a biguanide) is recommended as first-line treatment [8] , with a variety of therapies available as second-and third-line agents if treatment with metformin is insufficient to achieve desired A1C levels or if patients exhibit intolerance to metformin. Liraglutide is a long-acting, GLP-1 receptor agonist administered through a once-daily injection.
Adherence to diabetes medications is generally poor [9, 10] . Several studies have demonstrated a link between adherence and diabetes-related outcomes, including A1C levels [4, [10] [11] [12] [13] [14] [15] . In one study, the lower A1C achieved from greater adherence was comparable to that achieved with additional medication [16] . Persistence to prescription fills has also shown to be associated with a reduction in costs and rates of hospitalizations within Medicare patients [17] .
However, previous research on adherence and persistence to diabetes medication is primarily limited to oral antidiabetic (OAD) medications or insulin. In short, there is a paucity of data examining the association of adherence or persistence and subsequent clinical outcomes and costs within the GLP-1 receptor agonist therapeutic space. To expand the current knowledge and understanding of the clinical and economic outcomes associated with liraglutide, we sought to examine the impact of both adherence and persistence to once-daily liraglutide on glycemic control and healthcare costs in a real-world adult T2D population.
METHODS

Study Design and Data Sources
A retrospective cohort study was conducted using administrative claims from a large, US by the number of days in the follow-up period [12] . For this study, the PDC was dichotomized into C0.80 (adherent) and \0.80 (nonadherent). The threshold of 0.80 is commonly used, including by both the PQA and CMS [18, 19] . For completeness, as well as for use in sensitivity analyses, the Medication Possession 
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RESULTS
Sample Selection and Baseline Characteristics
After applying all inclusion and exclusion criteria, the final study population included a total of 1321 liraglutide patients with T2D (Fig. 1) . The mean (SD) age of the sample was 53.0 (9) years, and just over half (51%) were male ( Table 1 ).
The mean (SD) PDC was 0.59 (0.31); 454 patients (34%) were classified as adherent by way of a PDC of at least 80%. Sixty percent of patients were persistent for the entire 365-day follow-up period, and the mean (SD) length of persistence was 263 (136) days. Adherent patients were slightly older and more frequently male, while the mean DCSI was similar between adherent and non-adherent patients (0.57 vs. 0.59, p = 0.783, 
A1C Outcomes
Unadjusted A1C outcomes are shown in Table 2 . The reduction in mean A1C from baseline to follow-up was greater in adherent patients compared with non-adherent patients (0.81% vs. 0.42%, p\0.001) and in persistent patients than in non-persistent patients (0.78% vs. 0.21%, p\0.001). Additionally, when compared with the non-adherent cohort, those in the adherent cohort were more likely to achieve A1C goals of \7.0% (50% vs. 39%, p\0.001) and B6.5% (35% vs. 26%, p = 0.001), and were more likely to have at least a 1.0% reduction in their A1C (38% vs. 32%, p = 0.022). Similar results were seen when persistence cohorts were compared; A1C levels \7.0% and B6.5%, as well as A1C reductions of at least 1.0%, were more often attained by persistent patients than non-persistent patients (p\0.001 for all three outcomes).
Adjusted, multivariate analysis of the A1C outcomes confirmed the unadjusted results (Fig. 2a, b) . Specifically, adherent patients had a significantly larger decrease in A1C and were more likely to achieve at least a 1.0% reduction in A1C than their non-adherent counterparts 64 (5) 23 (5) 41 (5) 0.786
36 (5) 28 (5) 0.510 271 (21) 103 (23) 168 (19) 0.157
172 (22) 99 (19) 0.215
Number of baseline OAD medications, mean (SD) (8) 37 (8) 74 (9) 0.810
68 (9) 43 (8) 0.808
Non-alcohol fatty liver disease 52 (4) 19 (4) 33 (4) 0.737
40 (5) 12 (2) Table 3 ). When medical costs (which include costs for ambulatory visits, ER services, IP services, and other services) and pharmacy costs were summed, the result was a higher total healthcare cost among adherent patients ($9081 vs. $7717, p = 0.028; Table 3 ), on average. After adjustment, total diabetesrelated healthcare costs remained significantly higher for the adherent group (p = 0.005), with a predicted (95% confidence interval) cost of $9419 ($8574-$10,308) versus $7667 ($6903-$8573) for non-adherent patients (Fig. 3a) . Diabetes-related medical services costs were lower for persistent patients (adjusted model p value = 0.017), with a predicted cost costs, however, were higher for persistent patients than for non-persistent patients driven by higher pharmacy costs (Table 3 ; Fig. 3b ; adjusted model p value = 0.010).
DISCUSSION
Liraglutide patients who were adherent had better A1C outcomes and higher total diabetes-related healthcare costs than their non-adherent counterparts-driven by higher insulin. However, our mean adherence rate of 59% is within the range of 36-87% reported by Lee et al. [10] , although the authors measured adherence by MPR and included OADs and insulin. In a 2006 article, Ho et al. [12] reported that 79% of patients had PDC of at least 80%, which is noticeably higher than in our study, where only 34% had a PDC C80%. However, the PDC in the article by Ho et al. was a summary measure potentially of multiple medications, and referred to oral hypoglycemic agents. A study by Rhee et al. [14] reported an adherence of[75% in only 8% of patients, but the study years were 1991 through 2001 and adherence was measured as the percentage of visits in which self-reported diabetic medication use was as recommended at the preceding visit. In other studies offering a direct comparison of our findings of adherence to liraglutide, patients using liraglutide between 2010 and 2011 had a mean MPR of 70%, with 46% of patients being at least 80% adherent [26] . In another, more recent study involving GLP-1 receptor agonist use, 14,211 liraglutide patients had a median unadjusted PDC of 0.72 [27] . In our study, the average adherence rate was 0.65 using PDC and 72% using MPR with 45% of patients having an MPR of at least 80%, indicating a very similar level of adherence to these studies.
Although our study suggests that better adherence and persistence are associated with better A1C outcomes, there are potential barriers to adherence that need to be addressed. Patient attitudes, beliefs, and knowledge about diabetes, as well as culture, language capabilities, financial resources, comorbidities, and social support, have all been cited as potential barriers [28] . Other challenges for patients may include paying for medications, remembering doses, reading prescription labels, and obtaining refills [29] . More frequent administrations may also be linked to adherence, as taking more than two doses of diabetes medication daily has been associated with higher A1C levels [29] , and in a comparison of injectable GLP-1 receptor agonists, patients using once-daily liraglutide were more adherent than those using twicedaily exenatide [26] .
Claims database analysis allows for estimation of real-world treatment patterns, and the strength of our analysis derives from the large, geographically diverse population studied. The plans used for analysis include a wide geographic distribution across the US, and therefore provide the capability for generalization to managed care populations on a national level, although such generalizations should be made with caution since those selected for this analysis may represent a select patient population. All retrospective database analyses are subject to certain limitations, however, and the results of this study must be interpreted with appropriate consideration of these limitations. Claims data are collected primarily for payment purposes, not research, and are subject to coding errors. The presence of a claim for a filled prescription does not necessarily indicate that the medication was consumed or that it was taken as prescribed. Additionally, the data have no information on patient weight, body mass index, or blood pressure. Lab results were only available for a subset of patients (those without lab data were excluded), and only include those performed by a lab during a patient visit; therefore, they may 
CONCLUSION
In this study, we sought to examine how adherence and persistence to once-daily liraglutide impact glycemic control and healthcare costs in a real-world T2D population. Patients included in this study who were adherent or persistent to liraglutide had better adjusted A1C outcomes than those who were not. Persistent patients had significantly lower diabetes-related medical costs compared to patients discontinuing liraglutide. However, total diabetes-related costs were higher in adherent and persistent patients than in their non-adherent and nonpersistent counterparts, which were largely driven by their higher pharmacy costs. This study highlights the importance of adherence and persistence on diabetes control and associated healthcare costs. These results will assist payers and policy makers in making informed decisions by highlighting the impact and importance of medication adherence to liraglutide on clinical and economic outcomes. 
